Company intelligence / Profile preview
9Bio Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
All pipeline programs are in discovery or preclinical development. The company has received multi-year federal funding to advance its lead candidates through rigorous preclinical safety and efficacy studies required for regulatory approval of clinical testing. No human clinical results have been reported yet.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugatesEngineered cytokinesProtein-based therapeuticsCAR T cellsLigand/receptor mimetics
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on 9Bio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9Bio Therapeutics.